Pentadecapeptide BPC
Pentadecapeptide BPC
Also known as: BPC Variant, Stable BPC, BPC-157 Analog
Overview
Key Facts
Primary Goal: A stabilized variant of the BPC pentadecapeptide family, designed to improve bioavailability and extend activity
A stabilized variant of the BPC pentadecapeptide family, designed to improve bioavailability and extend activity. Shares the core healing mechanisms of BPC-157 with modifications aimed at enhanced oral stability. Half-Life 4-6 hours (estimated) Typical Dose 250–500 mcg Frequency 1-2x daily Cycle Length 4-12 weeks
Dosing Information
Half-Life
4-6 hours (estimated)
Typical Dose
250–500 mcg
Frequency
1-2x daily
Cycle Length
4-12 weeks
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Preclinical data supports similar healing profiles to BPC-157 with potentially improved pharmacokinetics for oral dosing. Limited published literature compared to BPC-157; most data derives from comparative analog studies.
Frequently Asked Questions
Common questions about Pentadecapeptide BPC
UK-Specific Information
Exclusive data points and guidance for UK residents using Pentadecapeptide BPC
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.